[18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a pilot study

CONCLUSIONS: The decline in [18F]FTT uptake shortly after PARPi initiation provides a measure of drug-target engagement and shows promise as a biomarker to guide PARPi therapies in this pilot study. These results support additional pre-clinical mechanistic and clinical studies in subjects receiving PARPi +/- combination therapy.PMID:36441795 | DOI:10.1158/1078-0432.CCR-22-1602
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Source Type: research